FDA declines to grant approval for Gilead Sciences' HIV treatment
The US Food and Drug Administration (FDA) has declined to grant approval for Gilead Sciences’ investigational therapy lenacapavir for HIV.
📰 Subchild Level Menu Hover News
Page 2 - Subchild Level Menu Hover News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Subchild Level Menu Hover. Real-time updates on events, politics, business and more.
ViiV Healthcare gets FDA nod for two-month dosing of Cabenuva
ViiV Healthcare has secured the US FDA approval for the expanded labelling of Cabenuva (cabotegravir, rilpivirine) to treat HIV-1 in adults.
Neogene Therapeutics signs global license agreement with NCI
Biotechnology firm Neogene Therapeutics has signed an exclusive, global license agreement with the National Cancer Institute (NCI) for a portfolio of T cell receptor (TCRs) targeting KRAS and TP53 mutations for the treatment of patients suffering with cancer.
AbbVie seeks approval for upadacitinib to treat nr-axSpA
Abbvie has submitted applications to the US FDA and the EMA to obtain approvals for upadacitinib (RINVOQ) to treat nr-axSpA.
Gerresheimer AG extends CEO Dietmar Siemssen's Contract by Five Years - Pharmaceutical Business review
At its meeting yesterday, the Supervisory Board of Gerresheimer AG extended the contract with CEO Dietmar Siemssen to the end of October 2026. Dietmar Siemssen has been CEO
Roche gets FDA breakthrough therapy for tiragolumab PD-L1-high NSCLC
Roche has secured breakthrough therapy designation from the US FDA for tiragolumab plus Tecentriq as a first-line treatment for people with NSCLC whose